Risk Stratification for Sudden Cardiac Death in Patients with Non-Ischemic Dilated Cardiomyopathy
Author Information
Author(s): Shekha Karthik MD, Ghosh Joydeep MD, Thekkoott Deepak MD, MRCP (UK), Greenberg Yisachar MD
Primary Institution: Maimonides Medical Center (Mount Sinai Health System)
Hypothesis
How can we effectively identify patients with non-ischemic dilated cardiomyopathy who are at risk for sudden cardiac death?
Conclusion
Implantable cardioverter defibrillators (ICDs) significantly reduce the risk of sudden cardiac death in patients with non-ischemic dilated cardiomyopathy, particularly in those with specific risk factors.
Supporting Evidence
- Patients with symptomatic NIDCM and documented ventricular tachycardia or ventricular fibrillation have a mortality rate of up to 22% in the first two years after diagnosis.
- ICD therapy has been shown to significantly reduce arrhythmic deaths in patients with NIDCM.
- The SCD-HeFT trial demonstrated that ICD implantation saves lives in patients with class II or III heart failure.
Takeaway
Doctors are trying to figure out which heart patients are most likely to have serious problems so they can help them with special devices that can save their lives.
Methodology
The review analyzes existing data on risk stratification methods and their clinical implications for patients with non-ischemic dilated cardiomyopathy.
Potential Biases
The review may be biased due to the inclusion of studies with varying methodologies and patient populations.
Limitations
Many studies reviewed were underpowered and non-randomized, limiting the strength of the conclusions.
Participant Demographics
The study primarily involves patients with non-ischemic dilated cardiomyopathy, including those with varying ejection fractions and functional classes.
Statistical Information
P-Value
0.06
Confidence Interval
95% CI 4-45%
Statistical Significance
p ≤ 0.05
Want to read the original?
Access the complete publication on the publisher's website